Opinião de médicos brasileiros sobre o tratamento da COVID-19
DOI:
https://doi.org/10.5020/18061230.2021.12473Keywords:
Infecções por Coronavirus, Tratamento Farmacológico, Hidroxicloroquina, CorticosteroidesAbstract
Objetivo: Investigar a opinião de médicos brasileiros sobre o tratamento precoce da COVID-19 com hidroxicloroquina/cloroquina e azitromicina em pacientes com suspeita clínica e sobre o tratamento com corticoterapia na fase inflamatória da doença. Métodos: Trata-se de uma pesquisa de opinião, com amostragem por conveniência, com médicos atuantes no Brasil. A coleta dos dados ocorreu no período de 26 de maio a 8 de junho de 2020 (13 dias), por meio de um formulário Google, disponibilizado publicamente nas redes sociais e aplicativos de comunicação. Realizou-se uma análise descritiva dos dados, teste de independência, teste T Student e modelo de regressão logística com análise multivariada. Resultados: A pesquisa contou com 1.020 médicos participantes, com média de 21,9 anos de formado. 72,4% dos participantes apresentaram-se a favor do tratamento precoce com hidroxicloroquina/cloroquina e azitromicina e 89,7% dos médicos apresentaram-se favoráveis ao uso da corticoterapia para o tratamento da fase inflamatória da COVID-19. Constatou-se também que participantes com maior idade, com residência médica, atuantes nas regiões Nordeste e Norte possuíam mais chances de serem favoráveis aos tratamentos. Por outro lado, profissionais especialistas em medicina intensiva, infectologia e pneumologia, além de atuantes nas unidades de terapia intensiva, mostraram-se mais desfavoráveis. Conclusão: A maioria dos médicos investigados nesta pesquisa de opinião mostrou-se a favor do tratamento precoce apresentado e do uso da corticoterapia no tratamento da COVID-19. Já os especialistas em medicina intensiva, infectologia e pneumologia e profissionais atuantes nas Unidades de Terapia Intensiva mostraram-se mais desfavoráveis.
Downloads
References
WHO - Worl Health rganization. 2020 [acesso 24 de outubro de 2020]. Disponível em: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
Brasil, Painel Coronavírus. 2020 [acesso 24 de outubro de 2020]. Disponível em: https://covid.saude.gov.br/.
Siddiqi HK, Mehra RM. COVID19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. Journal of heart and lung transplantation. 2020;39(5):405-407.
Ypuselfi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaei, Eslami M, et al. A global treatments for coronaviruses incluing COVID-19. Journal of Cellular Physiology. 2020 Dec;235(12):9133-9142. doi: 10.1002/jcp.29785. Epub 2020 May 11. PMID: 32394467; PMCID: PMC7273044.
Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323(1):264‐268. doi:10.1016/j.bbrc.2004.08.085.
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. Published 2005 Aug 22. doi:10.1186/1743-422X-2-69.
Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55(5):105960. doi:10.1016/j.ijantimicag.2020.105960.
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. Published 2020 Mar 18. doi:10.1038/s41421-020-0156-0.
Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Medicine and Infectious Disease. 2020. doi: https://doi.org/10.1016/j.tmaid.2020.101791.
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 [published online ahead of print, 2020 May 7]. N Engl J Med. 2020;NEJMoa2012410. doi:10.1056/NEJMoa2012410
Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(4):e208857. doi:10.1001/jamanetworkopen.2020.8857
Rosenberg ES, Dufort EM, Udo T, Wilberschield LA, Kumar J, Tesoreiro J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. Published online May 11, 2020. doi:10.1001/jama.2020.8630
Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844. Published 2020 May 14. doi:10.1136/bmj.m1844
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. Published 2020 May 14. doi:10.1136/bmj.m1849
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [published online ahead of print, 2020 May 22]. Lancet. 2020;S0140-6736(20)31180-6. doi:10.1016/S0140-6736(20)31180-6
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 Jul 23:NEJMoa2019014. doi: 10.1056/NEJMoa2019014. Epub ahead of print. PMID: 32706953; PMCID: PMC7397242.
Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. COALITION COVID-19 Brazil II Investigators. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020 Oct 3;396(10256):959-967. doi: 10.1016/S0140-6736(20)31862-6. Epub 2020 Sep 5. PMID: 32896292.
Zhong H, Wang Y, Zhang Z, Liu Y, Le K, Cui M, et al. Efficacy and Safety of Current Therapeutic Options for COVID-19 - Lessons to Be Learnt From SARS and MERS Epidemic: A Systematic Review and Meta-Analysis. Pharmacol Res.2020;104872. doi: 10.1016/j.phrs.2020.104872
Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. Clin Infect Dis. 2020; ciaa601. doi:10.1093/cid/ciaa601
Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv preprint doi: https://doi.org/10.1101/2020.06.22.20137273
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17:NEJMoa2021436. doi: 10.1056/NEJMoa2021436. Epub ahead of print. PMID: 32678530; PMCID: PMC7383595.
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. COALITION COVID-19 Brazil III Investigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020 Sep 2;324(13):1–11. doi: 10.1001/jama.2020.17021. Epub ahead of print. PMID: 32876695; PMCID: PMC7489411.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Sep 2;324(13):1–13. doi: 10.1001/jama.2020.17023. Epub ahead of print. PMID: 32876694; PMCID: PMC7489434.
Falavigna M, Colpani V, Stein C, Azevedo LC, Bagattini AM, Brito GV, et al. Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia. Rev Bras Ter Intensiva. 2020;32(2):166-196.
Sociedade Brasileira de Infectologia. INFORME DA SOCIEDADE BRASILEIRA DE INFECTOLOGIA SOBRE O NOVO CORONAVÍRUS N° 14: DEXAMETASONA NO TRATAMENTO DA COVID-19 Elaborado em 16/06/2020. Acesso [10 de junho de 2020]. Disponível em: https://web.infectologia.org.br/wp-content/uploads/2020/07/Informe-14-deexametasona-covid-19.pdf.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Brazilian Journal in Health Promotion
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitted manuscripts must be exclusively destined to RBPS and are not allowed to be submitted to another journal. When submitting the manuscript, authors must include the Declaration of Responsibility and Assignment of Copyright signed by all authors. The document must describe individual contribution to the preparation of the manuscript and be submitted in a pdf format. The author may deposit the final version of the article with post-print peer review in any repository or website under the Creative Commons Attribution 4.0 International License.